Bluejay Diagnostics advances clinical trials and manufacturing for sepsis test in Q1 2026.

Bluejay Diagnostics reported progress in Q1 2026 on its Symphony IL-6 test for sepsis monitoring, enrolling about 680 of 750 patients in a pivotal clinical study. The company resolved manufacturing issues with its Symphony cartridges and is preparing for FDA regulatory submission. With $3.7 million cash and a $1.9 million net loss, Bluejay focuses on clinical, manufacturing, and regulatory milestones to enable rapid near-patient testing for critical care. The next steps include completing validation and pursuing commercialization.